MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
March 14 2018 - 8:00AM
MannKind Corporation (NASDAQ:MNKD) focused on the development and
commercialization of inhaled therapeutic products for patients with
diseases such as diabetes and pulmonary arterial hypertension,
announced today that its Chief Executive Officer, Michael Castagna,
will present at the Oppenheimer 28th Annual Healthcare
Conference on Tuesday, March 20, 2018 at 3:20 PM (Eastern Time) at
the Westin New York Grand Central. Interested
parties can access a link to the live webcast of the presentations
from the News & Events section of the Company's website at
http://www.mannkindcorp.com. ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and
commercialization of inhaled therapeutic products for patients with
diseases such as diabetes and pulmonary arterial hypertension.
MannKind is currently commercializing Afrezza® (insulin human)
inhalation powder, the Company's first FDA-approved product and the
only inhaled rapid-acting mealtime insulin in the United States,
where it is available by prescription from pharmacies nationwide.
MannKind is headquartered in Westlake Village, California, and has
a state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
Company Contact:Rose AlinayaSVP Investor
Relations818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024